Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense ...

Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...

Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s ...

India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...

India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia, ...

Immuneel Therapeutics introduces Qartemi, India's first personalised CAR T-cell therapy for B-NHL, offering affordable ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

UNC Lineberger Comprehensive Cancer Center researchers have discovered a three-drug combination that enhances the generation ...